Navigation Links
Hard to Treat Diseases (HTDS.PK) Business Summary Update
Date:12/7/2009

SHENZHEN, China, Dec. 7 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS.PK) www.htdsmedical.com is using this opportunity to update its followers on the development of several previously announced events, which remain unresolved and or pending. These are Slavica Biochem's move into the Revenue Mode, Slavica's research expansion and pending EU Stem Cell Bank merger, HTDS' Africa Opportunity, HTDS' Pink Sheets "skull and bones" rankings, and the expected Q4 results.

HTDS and Slavica Biochem plan to start capitalizing on Slavica's research and move from purely Research and Development Mode into a Revenue Mode. Slavica Biochem wants to take full advantage of its research achievements. Its management foresees the first revenues commencing in 2010.

HTDS management also continues due diligence with the EU stem cell company regarding the merger discussions. In the light of these discussions, Slavica is exploring an opportunity to either commence its own stem cell bank, or in a capacity as a consultant - advisor to other European companies venturing in the stem cell marketplace. Both options will afford the company with an opportunity to generate substantial revenues without any dilution.

HTDS management is also exploring the options of expanding Slavica's research activity. This newly discussed project focuses on the methodplogy for treatment of damaged articular cartilage, namely, this medical process, which consists of autologous implantation of in-vitro cultivated chondrocytes (the cartilage-forming cells). This new technique is one of the most important orthopaedic achievements of this century. See Pink Sheets Filing November 24 2009 http://www.pinksheets.com/otciq/ajax/showFinancialReportById.pdf?id=26604

The research team from Slavica Biochem continues discussions for technology sharing with an EU based bio company that already deploys this technology into practice.

HTDS also wants to bring the attention back to the 'Africa Opportunity' filling form October 16, 2009. http://www.pinksheets.com/otciq/ajax/showFinancialReportById.pdf?id=25196

In order to meet the growing demands of the sub-Saharan Africa, the International Finance Corporation (http://www.ifc.org/) estimated that the region's health care, relying strongly on private sector, requires an investment of $25 to $30 billion USD, coming mainly from the US government. HTDS still explores the ways and means as how to prepare and fulfill any potential orders, and estimates its capacities and capabilities in order to capitalize from this opportunity.

Lastly, HTDS is considering to filing a formal complaint with USA regulators regarding the "Skull and Bones" ranking on Pink Sheets, as this ranking restricts certain normal trading activities of the security.

With recently announced contracts and the current contracts pending, which HTDS sees coming to fruition soon, the company expects a strong Q4 finish.

To receive future updates via email, including quarterly newsletters and company updates that may not be newsworthy, however important to the reader and followers of the company, please sign up today free at www.minamargroup.com/updates

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases Inc. that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases Inc.'s control. In addition to those discussed in Hard to Treat Diseases Inc.'s press releases, public filings, and statements by Hard to Treat Diseases Inc.'s management, including, but not limited to, Hard to Treat Diseases Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For any investor relations matters, please contact www.minamargroup.net/helpdesk; Investor Relations Department Inquiry, www.minamargroup.net (IR); For (M&A) and Corporate Matters, www.minamargroup.com

SOURCE Hard to Treat Diseases


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nutra Pharma Completes FDA Submission for Nyloxin OTC and Nyloxin Rx -- Over-the-Counter and Prescription Treatments for Chronic Pain
2. New study finds barriers to pain treatment in children with sickle cell disease
3. Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease
4. New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer
5. New Gene Findings Will Help Guide Treatment in Infant Leukemia
6. Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders
7. Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care
8. Epilepsy patients caught in treatment gap are not getting state-of-the-art care
9. Lexi-Comp Focused on Improving Patient Communication in Healthcare Institutions Treating Diverse Patient Populations
10. Miami Dentist Dr. H.A. Nassery Treats Local Teen Golf Star and Helps Improve Her Performance
11. NYU Langone Medical Center Study Shows VNS Therapy is a Safe and Effective Treatment for Refractory Epilepsy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills ... specialty vendors and unique items from across the nation, this holiday-themed event will raise ... offered by the VNA. The boutique will be open Saturday, November 4 (10:00 ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Yisrayl Hawkins, ... week that explains one of the most popular and least understood books in the ... cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed it ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “The Journey: ... faced every danger possible to save lost souls in the Philippines. “The Journey: From ... Carole is a dedicated teacher of the Bible. She has taught all ages and ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and ... apnea using cutting-edge Oventus O2Vent technology. As many as 18 million Americans ... frequent cessation in breathing. Oral appliances can offer significant relief to about 75 ...
(Date:10/12/2017)... , ... October 12, 2017 , ... IsoComforter, Inc. ( ... announced today the introduction of an innovative new design of the shoulder pad. ... you get maximum comfort while controlling your pain while using cold therapy. By utilizing ...
Breaking Medicine News(10 mins):
(Date:9/22/2017)... 2017 AVACEN Medical (AVACEN) announced that its ... helping those with the widespread pain associated with fibromyalgia ... in Essex, England commented, "I ... experiencing no sleep at all, tremendous pain, with every ... recommend [the AVACEN 100] enough, how this has and ...
(Date:9/18/2017)... , Pa. and KALAMAZOO, Mich. , Sept. ... Penn. , and OptiMed Specialty Pharmacy of ... partnership to offer a strategic hub service that expedites ... highly sought-after personal spirometer, Spiro PD 2.0, and wellness ... A spirometer is a medical device used to measure ...
(Date:9/12/2017)... 12, 2017   EcoVadis , the leading platform for environmental, social ... annual edition of its Global CSR Risk and Performance Index. The report ... based on Scorecard Ratings that analyzed nearly 800,000 data points across the ... ... ...
Breaking Medicine Technology: